Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Orally disintegrating tablet Stories

2013-01-02 12:22:29

PITTSBURGH, Jan. 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base). These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt®...

2012-10-09 15:25:00

PITTSBURGH, Oct. 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg. Prednisolone Sodium Phosphate ODT is the generic version of Shionogi's Orapred ODT(®), which is indicated for the treatment of certain pulmonary diseases such as asthma. Additionally, the...

2012-10-02 02:30:05

MIAMI, Oct. 2, 2012 /PRNewswire/ -- Fuisz Pharma announced today a patented film formulation for enhanced drug delivery performance. The seminal patent for this technology issued as United States Patent 8,241,661 ("Biocompatible Film with Variable Cross-Sectional Properties"). Joseph Fuisz Esq., managing member for Fuisz Pharma, explained: "It is understood that bi-layer film compositions can offer improved buccal absorption characteristics by retarding the drug that is lost to salivary...

2012-09-11 22:21:54

GREENWOOD VILLAGE, Colo., Sept. 12, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today that it has entered into a definitive agreement with Ethypharm Ltd for the manufacturing of Zertane(TM), Ampio's drug for the treatment of premature ejaculation. Zertane(TM) is...

2012-05-23 06:26:27

CRANFORD, N.J., May 23, 2012 /PRNewswire/ -- Akrimax Pharmaceuticals announced the launch of Suprenza(TM) (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogeneous obesity. Obesity is a major concern in the United States and has been associated with increases in high blood pressure, diabetes, and other diseases. Suprenza(TM) is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of greater than or...

2011-12-05 07:00:00

GREENWOOD VILLAGE, Colo., Dec. 5, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE--News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced it has signed an agreement to acquire certain rights relating to a patented orally disintegrating tablet (ODT) drug delivery technology that can be used worldwide to elevate the market acceptance of Ampio's Zertane(TM) product for...

2011-10-24 14:16:00

SILVER SPRING, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Schizophrenia is a chronic, severe, and disabling brain disorder. About 1 percent of Americans have this illness. Symptoms people with schizophrenia have...

2011-08-17 07:00:00

MIAMI, Aug. 17, 2011 /PRNewswire/ -- Fuisz Pharma (www.fuisz.com) today announced the publication of U.S. Patent Application US 20110182827 ("Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent"). This patent pending is directed towards a dosage form that includes a substance that is visible to a normal light or to a special light source in the buccal or vaginal cavity in order for medical personnel to confirm compliant use of a medication. The substance leaves behind a...

2011-07-25 01:00:00

MISSISSAUGA, Ontario, July 25, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada. Sublinox (zolpidem tartrate) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent...

2011-04-06 07:00:00

MIAMI, April 6, 2011 /PRNewswire/ -- Fuisz Pharma LLC announced today a new generation of solid dosage form designs that facilitate swallowing and esophageal transit. Clinical studies demonstrate that these new designs and principles thereof speed esophageal transit by 80%, ease the swallowing experience, and reduce the incidence of esophageal transit failure, as compared with the conventional tablet designs currently used. Joseph Fuisz, managing partner of Fuisz Pharma stated: "We stand...